Explore

Reuters Reuters
Pfizer pins post 2028 return to growth on new obesity and cancer drugs

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine.
Trendline Trendline
Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth

Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth

Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth
Trendline Trendline
Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth

Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth

Pfizer Exceeds Wall Street Expectations with Strong Q1 Earnings and Revenue Growth
Trendline Trendline
Obesity Surpasses Oncology as Leading Contributor to Biopharma Pipeline Value

Obesity Surpasses Oncology as Leading Contributor to Biopharma Pipeline Value

Obesity Surpasses Oncology as Leading Contributor to Biopharma Pipeline Value
Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline

LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline

LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline
Trendline Trendline
Pfizer Maintains 2026 Revenue Guidance Despite Decline in COVID-19 Products

Pfizer Maintains 2026 Revenue Guidance Despite Decline in COVID-19 Products

Pfizer Maintains 2026 Revenue Guidance Despite Decline in COVID-19 Products
Trendline Trendline
Sanofi Invests $294M to Expand AI Center in Toronto, Boosting Innovation

Sanofi Invests $294M to Expand AI Center in Toronto, Boosting Innovation

Sanofi Invests $294M to Expand AI Center in Toronto, Boosting Innovation
Trendline Trendline
Obesity Surpasses Cancer in Pharma R Returns, Deloitte Reports

Obesity Surpasses Cancer in Pharma R Returns, Deloitte Reports

Obesity Surpasses Cancer in Pharma R Returns, Deloitte Reports
Trendline Trendline
Nvidia's Strategy to Boost AI Exports Amidst Declining Market Share in China

Nvidia's Strategy to Boost AI Exports Amidst Declining Market Share in China

Nvidia's Strategy to Boost AI Exports Amidst Declining Market Share in China
Trendline Trendline
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings